Updating results

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia [ID1402]

In development [GID-TA10328] Expected publication date: TBC

Technology appraisal guidance In development

Galcanezumab for preventing migraine [ID1372]

In development [GID-TA10454] Expected publication date: 14 October 2020

Technology appraisal guidance In development

Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Highly specialised technologies guidance In development

Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

In development [GID-TA10164] Expected publication date: TBC

Technology appraisal guidance In development

Cardiac transplantation (rejection) - everolimus [ID114]

In development [GID-TAG232] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis (primary-progressive) - fingolimod [ID62]

In development [GID-TAG221] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - ximelagatran [ID376]

In development [GID-TAG377] Expected publication date: TBC

Technology appraisal guidance In development

Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466

In development [GID-TA10355] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264

In development [GID-TA10365] Expected publication date: TBC

Technology appraisal guidance In development

Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Technology appraisal guidance In development

Eltrombopag for untreated severe aplastic anaemia ID1198

In development [GID-TA10284] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]

In development [GID-TA10338] Expected publication date: TBC

Technology appraisal guidance In development

Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

In development [GID-TA10320] Expected publication date: TBC

Technology appraisal guidance In development

Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413

In development [GID-TA10329] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357

In development [GID-TA10322] Expected publication date: TBC

Technology appraisal guidance In development

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

In development [GID-TA10311] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

In development [GID-TA10324] Expected publication date: TBC

Technology appraisal guidance In development

Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260

In development [GID-TA10309] Expected publication date: TBC

Technology appraisal guidance In development

Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Technology appraisal guidance In development

Moxetumomab pasudotox for hairy-cell leukaemia [ID1142]

In development [GID-TA10288] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

In development [GID-TA10295] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172

In development [GID-TA10394] Expected publication date: TBC

Technology appraisal guidance In development

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: 19 August 2020

Technology appraisal guidance In development

Fetoscopic prenatal repair for open neural tube defects in the fetus

In development [GID-IPG10120] Expected publication date: 29 January 2020

Interventional procedures guidance In development

Open prenatal repair for open neural tube defects in the fetus

In development [GID-IPG10140] Expected publication date: 29 January 2020

Interventional procedures guidance In development

Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Highly specialised technologies guidance In development

Naldemedine for treating opioid-induced constipation ID1189

In development [GID-TA10291] Expected publication date: 05 June 2020

Technology appraisal guidance In development

KTE-X19 for treating relapsed or refractory mantle cell lymphoma ID1313

In development [GID-TA10312] Expected publication date: 06 December 0021

Technology appraisal guidance In development

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Technology appraisal guidance In development

Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331

In development [GID-TA10318] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with nab-paclitaxel for neoadjuvant treatment of early triple negative breast cancer [ID1574]

In development [GID-TA10531] Expected publication date: TBC

Technology appraisal guidance In development

Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

In development [GID-TA10542] Expected publication date: TBC

Technology appraisal guidance In development

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Sapropterin for treating phenylketonuria [ID1475]

In development [GID-TA10378] Expected publication date: TBC

Technology appraisal guidance In development

SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

In development [GID-MT526] Expected publication date: TBC

Medical technologies guidance In development

Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

In development [GID-TA10543] Expected publication date: TBC

Technology appraisal guidance In development

Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]

In development [GID-TA10508] Expected publication date: TBC

Technology appraisal guidance In development

Lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies ID1444

In development [GID-TA10477] Expected publication date: TBC

Technology appraisal guidance In development

Electrical stimulation to improve muscle strength in non-neurological chronic conditions

In development [GID-IPG10135] Expected publication date: TBC

Interventional procedures guidance In development

ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

In development [GID-TA10489] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis

In development [GID-IPG10117] Expected publication date: TBC

Interventional procedures guidance In development

Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

In development [GID-TA10277] Expected publication date: TBC

Technology appraisal guidance In development

TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

In development [GID-TA10221] Expected publication date: TBC

Technology appraisal guidance In development

Brolucizumab for treating wet age-related macular degeneration [ID1254]

In development [GID-TA10455] Expected publication date: TBC

Technology appraisal guidance In development

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab [ID1583]

In development [GID-TA10530] Expected publication date: 13 May 2020

Technology appraisal guidance In development

Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: 26 June 2020

Technology appraisal guidance In development

The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

In development [GID-MT517] Expected publication date: TBC

Medical technologies guidance In development

Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy ID1347

In development [GID-TA10264] Expected publication date: TBC

Technology appraisal guidance In development